Bioavailability assessment of a brompheniramine taste-masked pediatric formulation in a juvenile porcine model

Jiang Wang1, Diaa Shakleya1, George Giacoia2

  • 1Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation, US Food and Drug Administration, Silver Spring, Maryland, USA.

PubMed

Insights

A new taste-masked brompheniramine pediatric formulation shows comparable bioavailability to adult versions. This taste-masking approach using tannic acid improves medication compliance for children.

Area of Science:

  • Pharmaceutical Sciences
  • Pediatric Pharmacology
  • Drug Delivery Systems

Background:

  • Pediatric patients often exhibit poor compliance with medications due to bitter taste.
  • Adult formulations of brompheniramine are known for their unpleasant taste.
  • The National Institutes of Health Pediatric Formulation Initiative aims to improve pediatric drug formulations.

Purpose of the Study:

  • To develop and evaluate a taste-masked pediatric formulation of brompheniramine.
  • To compare the bioavailability of a novel taste-masked brompheniramine formulation against a marketed adult formulation.
  • To assess the efficacy of tannic acid for taste-masking brompheniramine.

Main Methods:

  • A juvenile porcine model was utilized for preclinical bioavailability assessment.
  • Oral administration of both marketed and taste-masked brompheniramine formulations.
  • Plasma samples analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for brompheniramine quantification.

Main Results:

  • A validated bioanalytical method demonstrated high accuracy and precision for brompheniramine measurement in plasma.
  • Bioavailability profiles of the taste-masked and marketed brompheniramine formulations were not significantly different.
  • The taste-masked formulation exhibited comparable pharmacokinetic properties to the adult formulation.

Conclusions:

  • Taste-masking brompheniramine with tannic acid is a viable strategy for pediatric formulation development.
  • The developed formulation offers a promising alternative to improve medication adherence in pediatric populations.
  • This approach supports the development of more palatable and effective pediatric medications.

Related Concept Videos

Bioavailability: Overview01:13

Bioavailability: Overview

Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.8K
Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH01:21

Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH

Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
1.4K
Methods for Studying Drug Absorption: In situ01:09

Methods for Studying Drug Absorption: In situ

In situ experiments, such as the Doluisio method and Single-Pass Perfusion technique, provide critical insights into drug uptake by simulating in vivo conditions for drug absorption.
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...
232